Share on StockTwits

Equities researchers at Raymond James dropped their price target on shares of BioMed Realty Trust (NYSE:BMR) from $24.00 to $23.00 in a research report issued on Friday, AR Network reports. Raymond James’ price objective would indicate a potential upside of 14.77% from the stock’s previous close.

Separately, analysts at KeyCorp downgraded shares of BioMed Realty Trust from a “buy” rating to a “hold” rating in a research note to investors on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $22.67.

BioMed Realty Trust (NYSE:BMR) traded up 1.26% during mid-day trading on Friday, hitting $20.04. The stock had a trading volume of 2,746,653 shares. BioMed Realty Trust has a one year low of $17.90 and a one year high of $23.13. The stock has a 50-day moving average of $18.70 and a 200-day moving average of $19.05. The company has a market cap of $3.821 billion and a price-to-earnings ratio of 116.41.

BioMed Realty Trust (NYSE:BMR) last released its earnings data on Thursday, February 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.02. The company had revenue of $158.00 million for the quarter, compared to the consensus estimate of $157.51 million. During the same quarter in the previous year, the company posted $0.36 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. Analysts expect that BioMed Realty Trust will post $1.43 EPS for the current fiscal year.

BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.